Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OPCON vs PREFRIN-A
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opcon is a brand name for the injectable solution containing desmopressin acetate, a synthetic analog of the antidiuretic hormone vasopressin. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption, reducing urine volume and osmolality.
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Management of diabetes insipidus,Control of polyuria and polydipsia following traumatic or surgical head injury,Treatment of nocturnal enuresis in children (off-label),Treatment of hemophilia A and von Willebrand's disease (type I) to increase factor VIII and von Willebrand factor levels (off-label)
Temporary relief of nasal congestion,Fever reduction,Mild to moderate pain relief
IV: 2-4 mg bolus, may repeat every 5-10 minutes as needed; max total dose: 10 mg.
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
The terminal elimination half-life is 8-12 hours in adults with normal renal function. This supports twice-daily dosing; half-life is prolonged in renal impairment.
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Primarily metabolized in the liver by disulfide bond reduction and peptide cleavage. Not significantly metabolized by cytochrome P450 enzymes.
Phenylephrine undergoes extensive first-pass metabolism by monoamine oxidase (MAO) in the liver and gut; acetaminophen is primarily metabolized by glucuronidation and sulfation, with minor CYP2E1 oxidation to a hepatotoxic metabolite NAPQI.
Renal elimination of unchanged drug accounts for approximately 65-70% of the administered dose; biliary/fecal excretion accounts for 20-25% following hepatic metabolism.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Approximately 80-85% bound to serum albumin and alpha-1-acid glycoprotein.
Phenylephrine: 50-60% bound to albumin and alpha-1-acid glycoprotein; Antazoline: ~20% bound to albumin.
Vd is approximately 1.5-2.0 L/kg, indicating extensive distribution into total body water and tissues.
Phenylephrine: Vd ~0.5 L/kg (distributes primarily into extracellular fluid); Antazoline: Vd ~2 L/kg (extensive tissue distribution).
Oral bioavailability is 85-90% due to minimal first-pass metabolism; intramuscular bioavailability is nearly 100%.
Ocular: <1% systemic bioavailability after topical administration; intranasal: 10-20% systemic bioavailability; oral: 2-5% due to first-pass metabolism.
No dosage adjustment required for renal impairment.
No dosage adjustment required for renal impairment.
Child-Pugh Class A and B: No adjustment. Child-Pugh Class C: Use with caution; consider dose reduction by 50%.
No dosage adjustment required for hepatic impairment.
IV: 0.02-0.04 mg/kg/dose every 5-10 minutes as needed; max single dose: 0.1 mg/kg; max total dose: 2 mg.
Children ≥6 years: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily. Children <6 years: not recommended.
Initiate at lower end of dosing range (e.g., 1-2 mg IV); titrate carefully due to increased sensitivity.
Use with caution due to increased risk of systemic absorption and adverse effects; consider lowest effective dose and frequency.
WARNING: SEVERE HYPONATREMIA. Desmopressin can cause hyponatremia which may be life-threatening if severe and untreated. Risk is increased in patients with conditions predisposing to hyponatremia or those receiving certain medications. Monitor serum sodium levels, especially in the elderly, children, and patients with increased intracranial pressure.
None.
Risk of severe hyponatremia and seizures; monitor fluid intake and serum sodium; use with caution in patients with fluid and electrolyte imbalances, renal impairment, cystic fibrosis, coronary artery disease, hypertension, and in the elderly; may increase blood pressure; avoid in patients with nephrotic syndrome or nephropathy; use with caution in patients receiving drugs that increase diuresis or thirst.
Avoid use in patients with hypertension, hyperthyroidism, diabetes, or cardiovascular disease. Risk of hepatotoxicity with acetaminophen overdose. Do not exceed recommended dose. Avoid concurrent use with MAO inhibitors.
Hypersensitivity to desmopressin or any component; moderate to severe renal impairment (e GFR < 50 m L/min/1.73 m²); hyponatremia or propensity for hyponatremia; primary nocturnal enuresis in patients with uncontrolled hypertension or history of electrolyte disturbances; von Willebrand's disease type IIB (off-label use)
Hypersensitivity to phenylephrine, acetaminophen, or any excipients. Severe hypertension or coronary artery disease. Concomitant use or within 14 days of MAO inhibitors.
No specific food interactions. Avoid alcohol as it may increase dizziness or drowsiness.
Avoid alcohol and products containing caffeine or other stimulants as they may increase the risk of cardiovascular adverse effects. No specific food restrictions beyond maintaining hydration.
Pregnancy Category C. First trimester: potential risk of congenital anomalies based on animal data; second and third trimesters: risk of fetal hypoxia and bradycardia due to uterine hypertonus.
Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction and reduced placental perfusion; risk of fetal hypoxia in third trimester. Pyrilamine: Class B in pregnancy; animal studies show no fetal harm. Avoid in first trimester due to theoretical risk of vasoconstriction. Use only if benefit outweighs risk.
Excreted in human milk in low concentrations; M/P ratio approximately 0.6. Use with caution due to potential for adverse effects in nursing infants.
Phenylephrine: minimal excretion in breast milk; M/P ratio unknown. Pyrilamine: not known if excreted. Antihistamines may cause drowsiness or irritability in infant. Avoid if possible due to lack of safety data. Consider alternative with more data.
No standard dose adjustment recommended; however, increased clearance in pregnancy may require higher doses to achieve therapeutic effect. Titrate based on clinical response and maternal-fetal monitoring.
No specific dose adjustment recommendations due to lack of pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration. Consider alternative agents if possible.
OPCON is a brand name for oxymetazoline, an α-adrenergic agonist used topically for nasal congestion. Avoid use beyond 3 days to prevent rhinitis medicamentosa. Contraindicated in narrow-angle glaucoma and after transsphenoidal hypophysectomy. Monitor for rebound congestion.
Prefrin-A combines phenylephrine (alpha-1 agonist vasoconstrictor) with pyrilamine (first-generation antihistamine). Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, or narrow-angle glaucoma. Avoid in patients taking MAO inhibitors or within 14 days of discontinuation. Rebound congestion can occur with prolonged use (>3 days). Monitor for CNS depression or paradoxical excitation in children.
Do not use for more than 3 days to avoid worsening congestion.,Spray once into each nostril twice daily as needed.,Avoid contact with eyes; rinse with water if contact occurs.,Do not share the bottle to prevent infection.,Consult a doctor if symptoms persist beyond 3 days.
Use exactly as directed; do not use for more than 3 days to avoid rebound congestion.,Avoid driving or operating machinery if drowsiness occurs, especially when combined with alcohol or other CNS depressants.,Do not use if you have high blood pressure, heart disease, thyroid problems, diabetes, or glaucoma unless directed by a doctor.,Discontinue use and consult a doctor if symptoms persist or worsen, or if you experience severe dizziness, headache, or irregular heartbeat.,Store at room temperature away from moisture and heat. Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OPCON vs PREFRIN-A, answered by our medical review team.
OPCON is a Ophthalmic Decongestant (Vasoconstrictor) that works by Opcon is a brand name for the injectable solution containing desmopressin acetate, a synthetic analog of the antidiuretic hormone vasopressin. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption, reducing urine volume and osmolality.. PREFRIN-A is a Ophthalmic Decongestant/Antihistamine Combination that works by PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OPCON and PREFRIN-A depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OPCON is: IV: 2-4 mg bolus, may repeat every 5-10 minutes as needed; max total dose: 10 mg.. The standard adult dose of PREFRIN-A is: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OPCON and PREFRIN-A in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OPCON is classified as Category C. Pregnancy Category C. First trimester: potential risk of congenital anomalies based on animal data; second and third trimesters: risk of fetal hypoxia and bradycardia due to uterin. PREFRIN-A is classified as Category C. Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.